Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2022Clinical Cancer ResearchOpen Access

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLi ChenYJYi‐Zhou JiangSWSong‐Yang Wu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chen et al. (2022) studied this question.

synapsesocial.com/papers/69daae36a6045d71bfa3dbd3https://doi.org/10.1158/1078-0432.ccr-21-4313
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study2018 · 641 citations
  2. 2Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer2021 · 236 citations